Tirzepatide Dosage: How the Titration Schedule Works

Why tirzepatide is started at a low dose

Tirzepatide activates receptors for two gut hormones — GIP and GLP-1 — that regulate appetite, gastric emptying, and blood-sugar signaling. Because this mechanism slows digestion, starting at a full therapeutic dose commonly causes significant nausea, vomiting, or diarrhea.

Titration is a deliberate warm-up strategy. Beginning at a sub-therapeutic dose and holding it for at least four weeks before stepping up gives the gastrointestinal tract time to adapt, which meaningfully reduces early side effects. The titration schedule in the FDA-approved labeling was built around exactly this principle: tolerability comes before dose escalation, not the other way around.

This article is educational. All decisions about your dose, pace of titration, and long-term maintenance dose must be made by your prescribing provider.

The FDA-approved tirzepatide titration schedule

The schedule below reflects the tirzepatide prescribing information for Zepbound and Mounjaro as reviewed by the U.S. Food and Drug Administration. Doses are given by subcutaneous injection once weekly.

• Weeks 1–4: 2.5 mg once weekly — starter dose only; not intended for long-term weight management
• Weeks 5–8 (minimum): 5 mg once weekly
• Weeks 9–12 (minimum): 7.5 mg once weekly
• Weeks 13–16 (minimum): 10 mg once weekly
• Weeks 17–20 (minimum): 12.5 mg once weekly
• Week 21 onward, if needed: 15 mg once weekly — the maximum labeled dose

Each step-up occurs no sooner than every 4 weeks. If a higher dose is not tolerated, your provider may delay or pause escalation — the schedule sets a minimum interval and a ceiling, not a rigid mandate. Your prescribing provider determines whether and when each increase is appropriate for you.

What the 2.5 mg starter dose is — and is not

The FDA labeling explicitly describes 2.5 mg weekly as a dose to initiate treatment and improve gastrointestinal tolerability. It is not considered a therapeutic weight-management dose on its own. Clinically meaningful weight loss in the SURMOUNT-1 trial occurred at the 5 mg through 15 mg maintenance doses.

It is common and normal for the first four weeks to bring minimal weight change. That is expected and by design. The starter phase is working as intended — building tolerance before therapeutic dosing begins. Feeling impatient during this phase is understandable; changing the dose without provider guidance is not safe.

Finding the right maintenance dose for you

Not every patient needs to reach 15 mg. The prescribing information supports continuing at the lowest dose that achieves adequate weight-management benefit with acceptable tolerability. In the SURMOUNT-1 trial, patients at 5 mg, 10 mg, and 15 mg all achieved statistically significant weight loss compared with placebo; higher doses produced greater average reductions on a group level, but individual responses vary considerably.

Your provider will assess your weight trend, side-effect burden, metabolic markers, and overall health to determine when you have found a dose that is working. The goal is the lowest effective dose for you — not automatically the highest available dose. Discuss your progress openly at every follow-up visit so your provider has the information needed to guide that decision.

How providers decide when to move up a dose

A dose increase is typically considered when all of the following apply:

• You have been on the current dose for at least 4 weeks
• Side effects — particularly nausea, vomiting, diarrhea, or constipation — are at an acceptable level
• Weight response at the current dose has plateaued and the clinical goal has not yet been reached

If side effects remain significant, your provider may extend the time at the current dose, suggest dietary adjustments, or discuss symptom-management strategies before stepping up. Never increase your own dose ahead of your provider's guidance. Doing so raises the risk of severe gastrointestinal side effects and may fall outside the terms of your prescription.

Injection timing, day consistency, and missed doses

Tirzepatide is injected subcutaneously once weekly. Choosing a consistent day of the week — and injecting at roughly the same time on that day — helps build a reliable routine and supports steady medication levels between doses.

General guidance from the tirzepatide labeling for missed doses:

• If 4 days or fewer have passed since your scheduled dose day, inject as soon as you remember, then return to your regular weekly schedule.
• If more than 4 days have passed, skip that dose entirely and resume on your next scheduled day.
• Never take two doses in the same week to compensate for a missed one.

For a fuller discussion of missed-dose scenarios — including what to do if you are unsure — see our dedicated missed-dose article. When in doubt, contact your prescribing provider before injecting.

Compounded tirzepatide: key differences patients should know

Some patients access tirzepatide through compounding pharmacies rather than the FDA-approved brand-name products (Zepbound for chronic weight management; Mounjaro for type 2 diabetes). Compounded tirzepatide is not FDA-approved. The FDA has not evaluated compounded formulations for safety, efficacy, or manufacturing quality in the same rigorous way it has reviewed Zepbound and Mounjaro.

Concentrations, inactive ingredients, titration conventions, and dosing instructions for compounded products may differ from the FDA-labeled schedule described in this article. If you are using a compounded product, follow the specific instructions provided by your prescribing provider exclusively — do not use the brand-name labeled schedule as a direct substitute. Nuv is not affiliated with Eli Lilly, the manufacturer of Zepbound and Mounjaro.